Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Welcome and Introduction to Vi3C

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Feb

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Welcome and Introduction to Vi3C

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer

Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC

FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer

MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer

Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy